Alnylam Pharmaceuticals Submits New Drug Application for Experimental Acute Hepatic Porphyria Drug
According to a press release from Alnylam Pharmaceuticals, the Massachusetts-based biopharmaceutical company has completed the submission of its New Drug Application (NDA) for givosiran — its experimental acute hepatic porphyria…